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axonal motor protein working in cargo transport along 
neurites. Variants in KIF1A were identiﬁed in different 
forms of neurodegenerative diseases with dominant and 
hereditary spastic paraparesis, SPG30. De novo heterozy-
gous dominant variants were found both in a dominant 
reported and in patients with different forms of progressive 
Abstract KIF1A gene encodes the kinesin 1a protein, an neurodegenerative diseases. We report the results of a 
genetic screening of 192 HSP patients, with the identiﬁ-
cation of four heterozygous variants in KIF1A in four 
cases, two of whom with family history for the disease. 
recessive inheritance. Homozygous recessive mutations Three of the four variants fall within the motor domain, a 
were found in the hereditary sensory and autonomic neu- frequent target for variants related to the AD-SPG30 sub-
ropathy type 2, HSAN2 and in a recessive subtype of type. The fourth variant falls downstream the motor 
domain in a region lacking any functional domain. The 
KIF1A-related patients show clinical pictures overlapping 
form of SPG30 (AD-SPG30) with one single family the known AD-SPG30 phenotype including pure and 
complicated forms with few differences. Of note, one of 
the families, originating from the Sicily island, carries the 
same variant p.S69L detected in the ﬁrst AD-SPG30 family 
of Finnish origin reported; differently from the ﬁrst one, the 
latter family shows a wide intra-familial phenotype vari-
ability. Overall, these data reveal a very low frequency of 
the AD-SPG30 subtype while conﬁrming the presence of 
amino acid residues in the motor domain representing 
preferential targets for mutations, thereby supporting their 
functional relevance in kinesin 1a activity. 
Keywords NGS-targeted resequencing _ 
Spastic paraparesis _ KIF1A _ Dominant 
inheritance 
Introduction 
The KIF1A gene encodes a neuron-speciﬁc family 1 kinesin 
protein termed kinesin 1a, responsible for fast anterograde 
transport of synaptic vesicle precursors along axons [1, 2]. 
Both recessive and dominant variants in KIF1A gene were 
reported associated with a wide range of phenotypes with a 
different degree of severity. Homozygous recessive muta-
tions in KIF1A were ﬁrst described in patients affected by a 
severe form of a neurodegenerative disorder known as 
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(HSAN2) [3] and in three consanguineous families with an 
autosomal recessive form of hereditary spastic paraparesis 
variants were found in a wide range of phenotypes as well. A 
speciﬁc mutation p.T99M was found in patients with intel-
lectual disability (ID), spasticity, and axial hypotonia [6] and 
in another patient with a more severe phenotype including 
optic atrophy, growth failure, and progressive cerebellar 
atrophy, in addition to ID and spasticity [7]. A partly over-
lapping phenotype such as a progressive encephalopathy 
with brain atrophy was recently found associated with de 
novo KIF1A mutations [8]. Several de novo mutations and 
variants were found in patients classiﬁed either as pure or 
complicated HSP [9] and in one family with a dominant 
segregation pattern of pure HSP [10]. In all cases, the age 
range of disease onset is from 1 to 30 years. In the compli-
cated phenotypes, the most common features accompanying 
spasticity are axonal neuropathy and brain cerebellar atrophy 
at the MRI [9, 10]. These authors suggested classifying both 
the recessive (AR) and the dominant (AD) forms of HSP 
associated with KIF1A variants as SPG30 [10]. The KIF1A 
atrophy are clustered in the motor domain of kinesin 1A, 
which is located in the N terminus of the protein (aa 1–365). 
It contains the key sequences for ATP and microtubules 
binding which are necessary for kinesin 1a movement along 
downstream of the motor domain such as the fork-head 
domain (FHA, aa 516–572) with the neck coil, CC1–FHA– 
(PH, aa 1676–1774) [11]. The homozygous mutations in AR-
SPG30 affect the distal part of the motor domain [4, 5] while 
downstream the motor domain of the protein [3]. 
Here we report the results of a screening of a large series 
of HSP patients for KIF1A mutations, with the identiﬁcation 
of four KIF1A variants in four index cases, two of whom 
showing family history for the disease. One of these two 
families carries the same dominant variant p.S69L detected 
in the ﬁrst AD-SPG30 family previously reported [9] while 
showing a different phenotype. Three of the variants are 
located in the motor domain, while one falls within the 
middle portion of the protein upstream the PH domain. 
Patients 
A series of 192 index patients with hereditary spastic 
paraplegia, HSP, were clinically evaluated and genetically 
hereditary sensory and autonomic neuropathy type 2 analyzed. The study was approved by the Ethics Com- 
mittee of the Scientiﬁc Institute E. Medea. Diagnosis of the 
HSP patients was based on the Harding criteria [12] for the 
termed SPG30 [4, 5]. De novo heterozygous dominant deﬁnition of the clinical status. Seventy ﬁve patients had 
clinically pure HSP forms, while 117 showed a compli-
cated phenotype characterized by a variable combination of 
axonal sensory-motor neuropathy, distal amyotrophy, and 
cognitive deﬁcits in addition to spastic paraplegia. Age at 
disease onset ranged from 1 to 65 years of age. Sporadic 
occurrence of the diseases was observed in 120 patients; 
either a recessive or a dominant segregation pattern was 
observed in 42 and in 30 patients, respectively. Blood 
specimens were obtained from the probands, from all the 
available members of the families and from control sub-
jects with informed consent. 
Sequencing 
For gene screening, a targeted next-generation sequencing 
(NGS) method was used that included 84 genes linked to 
HSP or overlapping diseases such as neuropathy, ataxia, 
and motor neuron diseases (Online Resource Table 1). 
variants associated with dominant and recessive SPG30       Target enrichment and ampliﬁcation were done with the 
subtypes and with the progressive encephalopathy with brain       HaloPlex kit (Agilent Technologies, Santa Clara, CA, 
USA) according to the manufacturer’s instructions and 
sequenced on MiSeq (Illumina, San Diego, CA, USA) as 
described in detail in Supplementary Methods. Variant 
ﬁltering steps and the relative results are reported in detail 
neurites. Additional functional domains are recognized as Online Resource, Table 2. Sanger Sequencing was used 
to conﬁrm all variants identiﬁed as previously described 
[13]. Accession no. of KIF1A cDNA and protein used for 
CC2–CC3, and a liprin alfa-binding and pleckstrin domain mutation nomenclature are NM_001244008.1 and 
NP_001230937.1, respectively. 
Predictions of variants’ pathogenicity were obtained 
the mutations associated with HSAN2 are located just using SIFT, PolyPhen-2, MutationTaster, MutPred, Pan- 
ther, and PROVEAN software (Online Resource Fig. 1). 
Results 
Genetic ﬁndings 
Search for KIF1A mutations through targeted NGS of 192 
HSP patients led to the identiﬁcation of four different 
heterozygous variants in the KIF1A gene, in two AD-HSP 
families and in two patients without family history for the 
diseases (Table 1; Fig. 1). No homozygous muta-
Materials and methods tions/variants were found. 
The variants, c.304G[A, p.G102S (novel), and 
c.499C[T, p.R167C (known [9]), were found in patients 
without family history of disease, P67809 and P116909, 
respectively. Parents were available for patient P67809 
only; for him we were able to demonstrate the de novo 
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in another change p.G102D in a previously reported patient 
[9]. 
In the dominant family P7814, the proband carries the 
dominant variant c.206C[T, p.S69L previously reported 
transmitted by the maternal grandfather (III-8) (Fig. 1); it 
was also detected in one of the four affected grandfather’s 
cousins (III-6), who was available for both genetic and 
Unfortunately, only the proband of the family was avail-
able for genetic and clinical evaluations; therefore, segre-
gation could not be checked. 
Three out of the four variants are located in the motor 
domain; only p.I1127T falls within a region apparently 
domain. However, as shown in Fig. 1, all residues involved 
in the changes are highly evolutionary conserved. The 
novel variants were absent in 600 Italian control subjects; 
in dbSNP, 1000 genomes and EVS databases predictions 
carrying heterozygous variants in KIF1A are summarized 
in Table 1, while detailed clinical description is provided 
complicated forms of HSP. Mild intellectual disability or 
axonal neuropathy is typically associated with spasticity in 
disease onset ranges from 1 to 63 years. The two familial 
cases here described originate both from Sicily Island and 
differ from the single AD-SPG30 family reported dis-
playing a pure HSP with early onset [10]. In the family 
P7814, disease onset was still in early childhood and 
adolescence. However, a wide intra-familial phenotype 
variability is observed mostly in terms of diseases severity, 
ranging from an early-onset progressive spasticity associ-
ated with learning disability in the proband to a very mild 
disability mainly due to leg stiffness in the proband’s 
mother, to a more severe phenotype in the maternal 
grandfather who displays also mild hand amyotrophy, 
superﬁcial, and deep sensory abnormalities in the lower 
limbs in addition to spasticity. For family P22413, only the 
origin of the variant in the proband. The substitution       proband was available for clinical and genetic evaluations 
p.G102S affects an amino acid residue (Gly102) involved       and thus reported in Table 1. Clinical data about the 
affected father (deceased) were reported by the proband. In 
this family, both the proband and her father manifested the 
ﬁrst symptoms of gait instability and unsteadiness in their 
sixties. These symptoms rapidly evolved into lower limbs 
[10]. The change was inherited from the mother and was spasticity in 2–3 years. The father became wheelchair 
bound in about 10 years and died at age 87. With exception 
of the late age of disease onset in patient P22413, the 
spectrum of clinical features displayed by these patients 
clinical evaluations. In the pedigree shown in Fig. 1, quite overlaps the clinical pictures previously described, 
additional members are reported as affected based on associated with KIF1A-related dominant forms of HSP [9, 
clinical information obtained from the proband’s parents 10]. 
and from the maternal grandfather. 
A fourth variant c.3380T[C, p.I1127T was detected in 
patient P22413 with a family history for the disease. Discussion 
The genetic screening of a large series of HSP patients led 
to the identiﬁcation of four heterozygous variants pS69L, 
p.G102S, p.R167C, and p.I1127T, in the KIF1A gene in 
four HSP cases, two sporadics and two with dominant 
lacking any functional domain, just upstream the PH inheritance. Two of the four variants are novel, p.G102S 
and p.I1127T. Overall, the clinical phenotypes displayed 
by these patients overlap the range of phenotypes previ-
ously described conﬁrming a marked clinical variability 
associated with the AD-SPG30 subtype. 
for the novel variants indicate an impairment of protein            The three-generation family here described P7814, 
functions in all the cases (Online Resource Fig. 1).                   originating from the Sicily island, differs for several 
aspects from the single AD-SPG30 family so far reported 
Clinical ﬁndings                                                                          with early-onset pure HSP [10]. This Sicilian family indeed 
presents a range of phenotypes recapitulating the pheno- 
Clinical and neuroradiological features of the patients type variability shown by the sporadic cases so far repor- 
ted. Indeed, the mildest form of the disease is observed in 
the proband’s mother who had only a minimal disability 
as Online Resource. They show either pure (P116909) or with slight stiffness of the legs, pes cavus, positive 
Babinski sign, no intellectual disability, and no cerebellar 
signs. In the proband, the youngest affected of the family, 
the complicated HSP patients here described. Brain imag-       spasticity was associated with psychomotor delay and 
ing was normal in all of them but one, P22413. Age of       learning disabilities. The most severe form of the disease 
bFig. 1 a The Pedigree of the familial cases P7814 and P22413 
carrying the p.S69L and p.I1127T variant, respectively. Black and 
white symbols indicate affected and healthy subjects, respectively. 
Arrow indicates the proband, asterisks indicated the subjects 
analyzed. b Electropherograms of all mutations identiﬁed in the 
study and control sequences. The variant nucleotides are boxed. 
c Schematic representation of KIF1A protein domains with the 
missense mutations described in this work in the upper part. Novel 
variants are indicated in bold. Partial alignment of the amino acid 
sequences encompassing the protein region carrying the variant 
residues. Accession no. of the aligned sequences: H. sapiens 
NP_001230937.1, C. lupus NP_001161945.1, B. taurus XP_00520 
5116.1, M. musculus NP_032466.2 R. norvegicus XP_006245623.1, 
G. Gallus XP_003641781.1, D. rerio XP_005166002.1, and X. 
tropicalis XP_002933380.2 
was observed in the maternal grandfather who showed a 
abnormalities in the lower limbs in addition to spasticity. In 
this case, no intellectual disability was found. Based on the 
grandfather showed a similar complicated phenotype with 
the same disease course. In spite of this, the Sicilian family 
detected in the Finnish family [10]. A possible explanation 
for such a phenotype variability associated with the same 
p.S69L variant might be derived from the structural mod-
eling data available for the KIF1A motor domain [10]. 
Based on them, it appears that the S69 residue participates 
in the formation of the ATP-binding pocket, and the sub-
stitution of the serine residue for leucine could induce a 
conformational change likely breaking the interaction of 
the close residue Tyr67 with the ATP [10]. This would 
altering the overall structure of the KIF1A ATP-binding 
pocket [10]. The effect on ATP-binding stability in turn 
might variably affect protein function and, even more, 
protein dimerization and dimer stability, thereby explain-
ing the variability of the clinical outcome observed in the 
Sicilian family. 
Based on the family records available and on the dif-
ferent ethnic origins, it is unlikely that the Sicilian and 
Finnish families share a common origin. In line with this 
hypothesis is the demonstration of the de novo origin of the 
p.S69L variant in the Finnish family. On a different level, 
detected in the KIF1A motor domain explains ﬁnding the 
same nucleotides and amino acids being affected several 
times in unrelated patients. Indeed, the S69 residue in the 
KIF1A motor domain is not the only example for that. 
Additional KIF1A amino acid residues are now emerging 
as frequent targets of substitutions such as T99 [6–9], R216 
[8, 9], R167 ([9] and present study), E253, and R316 [8, 9], 
and even among the novel variants here detected, G102 has 
been found hit twice ([9] and present study). In fact, G102 
undergoes to the p.G102S substitution herein described and 
to another presumed pathological change (p.G102D) pre-
viously reported [9]. The G102 residue lies in the con-
served p-loop (GX4G
102
K[T/S]) of the ATP-binding 
reported substitution p.G102D disrupts the interaction with 
the phosphate region of ATP [9]. Although the change here 
described p.G102S, from Glycine to Serine, seems to be 
less dramatic in terms of charge and steric hindrance, it is 
likely that the key functional role of the p-loop has such 
strong sequence and structural requirements that even an 
apparently mild change cannot be tolerated. In line with 
that, apparently the two substitutions involving the same 
residue G102, p.G102D [9] and p.G102S (this study), are in 
mild hand amyotrophy, superﬁcial, and deep sensory both cases associated with a mild complicated phenotype 
characterized by ID and progressive spasticity in the ﬁrst 
case, or by axonal neuropathy in addition to ID and spas- 
family records, the affected cousins of the maternal ticity in the latter. Concerning the p.R167C substitution, 
the postulated effect is to weaken the binding of the motor 
domain of KIF1A to the microtubules thereby affecting 
shares the same dominant variant p.S69L previously kinesin 1a movements along the neurites [9]. Indeed, the 
R167 residue is located in the loop 8 which binds the 
microtubules in an ATP hydrolysis-independent manner. In 
line with that, the patients carrying the p.R167C variant, 
([9] and the one here described) both share a mild HSP 
phenotype. 
The proband of the second family P22413 carries the 
novel KIF1A variant p.I1127T, which is located down-
stream the motor domain in a region apparently lacking any 
recognized functional domain. Although family history of 
affect the stability of the ATP binding of KIF1A without patient P22413 indicates the presence of an affected 
deceased parent with overlapping clinical phenotype and 
age of disease onset, we do not have any chance to verify 
the segregation of the variant p.I1127T in the proband’s 
father. We can only observe that the variant residue is 
highly evolutionary conserved and that all software used 
predict pathological/damaging effects for the substitution. 
The localization and type of the substitution may determine 
a mild functional effect of the variant identiﬁed which can 
ﬁt with the late onset phenotype observed in the family. 
However, in the absence of any functional proof, at this 
stage, we favor the hypothesis the p.I1127T is a rare variant 
the evidence of so many de novo mutations/variants with an unknown signiﬁcance rather than a mutation. 
With regard to the novel variants detected in sporadic 
cases, although the range of clinical phenotype variability 
overlaps the one previously described for the AD-SPG30 
patients [9], few known features cannot be observed in the 
patients here reported. For instance, cerebellar atrophy, 
reported to be typically associated with the AD-SPG30 
subtype, cannot be found in the patients here described. In 
addition, EEG abnormalities or epilepsy, which were found 
in at least ﬁve patients previously reported [10], are not 
present in the patients of this study. Overall, the results of 
the screening of KIF1A gene in a large series of HSP 
patients indicate that KIF1A is not a frequent cause of HSP 
either pure or complicated forms. The lack of homozygous 
pocket of KIF1A motor domain. Based on structural       recessive mutations along with the few so far reported [4, 
modeling, the authors postulated that the previously       5] clearly suggests that recessive SPG30 is a very rare 
subtype of HSP. The identiﬁcation of heterozygous domi-
nant variants in 2 patients out of 120 sporadic and in 1 out 
of 30 dominant families (excluding the family with the rare 
variant of unknown signiﬁcance p.I1127T), while con-
ﬁrming a low frequency of the dominant SPG30 subtype, 
still justiﬁes the test of this gene in different forms of the 
HSP either with sporadic or familial occurrence regardless 
the age of disease onset. Additional studies on larger series 
 of patients are needed to assess the correct frequency of the 
dominant form of the SPG30 subtype. 
Acknowledgments     The authors wish to thanks the patients and 
their families for participation to this work and all referring clinicians 
for collaboration. This work was supported by the Italian Ministry of 
health under the frame of E-Rare-2, the ERA-Net for Research on 
Rare Diseases’’ Grant NEUROLIPID and Grant No. 2015 and 
5xMille. 
Compliance with ethical standards 
Conﬂicts of interest On behalf of all authors, the corresponding 
author states that there is no conﬂict of interest. 
Ethical standards All human studies have been approved by the 
appropriate ethics committee and have therefore been performed in 
accordance with the ethical standards laid down in 1964 Declaration 
of Helsinki and its later amendments. All persons gave their informed 
consent prior to their inclusion in the study. We have not included any 
details that might disclose the identity of the subjects in the study. 
References 
` 
1. Lee JR, Shin H, Ko J, Choi J, Lee H, Kim E (2003) Character-
ization of the movement of the kinesin motor KIF1A in living 
cultured neurons. J Biol Chem 278:2624–2629. doi:10.1074/jbc. 
M211152200 
2. Okada Y, Yamazaki H, Sekine-Aizawa Y, Hirokawa N (1995) 
The neuron-speciﬁc kinesin superfamily protein KIF1A is a 
unique monomeric motor for anterograde axonal transport of 
synaptic vesicle precursors. Cell 81:769–780. doi:10.1016/0092-
8674(95)90538-3 
3. Riviere JB, Ramalingam S, Lavastre V, Shekarabi M, Holbert S, 
Lafontaine J, Srour M, Merner N, Rochefort D, Hince P, Gaudet 
R, Mes-Masson AM, Baets J, Houlden H, Brais B, Nicholson GA, 
Van Esch H, Naﬁssi S, De Jonghe P, Reilly MM, Timmerman V, 
Dion PA, Rouleau GA (2011) KIF1A, an axonal transporter of 
synaptic vesicles, is mutated in hereditary sensory and autonomic 
neuropathy type 2. Am J Hum Genet 89:219–230. doi:10.1016/j. 
ajhg.2011.06.013 
4. Erlich Y, Edvardson S, Hodges E, Zenvirt S, Thekkat P, Shaag A, 
Dor T, Hannon GJ, Elpeleg O (2011) Exome sequencing and 
disease-network analysis of a single family implicate a mutation 
in KIF1A in hereditary spastic paraparesis. Genome Res 
21:658–664. doi:10.1101/gr.117143.110 
5. Klebe S, Lossos A, Azzedine H, Mundwiller E, Sheffer R, 
Gaussen M, Marelli C, Nawara M, Carpentier W, Meyer V, 
Rastetter A, Martin E, Bouteiller D, Orlando L, Gyapay G, El-
Hachimi KH, Zimmerman B, Gamliel M, Misk A, Lerer I, Brice 
A, Durr A, Stevanin G (2012) KIF1A missense mutations in 
SPG30, an autosomal recessive spastic paraplegia: distinct phe-
notypes according to the nature of the mutations. Eur J Hum 
Genet 20:645–649. doi:10.1038/ejhg.2011.261 
6. Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi 
K, Park AR, Spiegelman D, Dobrzeniecka S, Piton A, Tomitori 
H, Daoud H, Massicotte C, Henrion E, Diallo O, S2D Group, 
Shekarabi M, Marineau C, Shevell M, Maranda B, Mitchell G, 
` 
´ 
¨ 
Nadeau A, D’Anjou G, Vanasse M, Srour M, Lafreniere RG, 
Drapeau P, Lacaille JC, Kim E, Lee JR, Igarashi K, Huganir RL, 
Rouleau GA, Michaud JL (2011) Excess of de novo deleterious 
mutations in genes associated with glutamatergic systems in 
nonsyndromic intellectual disability. Am J Hum Genet 
88:306–316. doi:10.1016/j.ajhg.2011.02.001 
7. Okamoto N, Miya F, Tsunoda T, Yanagihara K, Kato M, Saitoh 
S, Yamasaki M, Kanemura Y, Kosaki K (2014) KIF1A mutation 
in a patient with progressive neurodegeneration. J Hum Genet 
59:639–641. doi:10.1038/jhg.2014.80 
8. Esmaeeli Nieh S, Madou MR, Sirajuddin M, Fregeau B, 
McKnight D, Lexa K, Strober J, Spaeth C, Hallinan BE, Smaoui 
N, Pappas JG, Burrow TA, McDonald MT, Latibashvili M, 
Leshinsky-Silver E, Lev D, Blumkin L, Vale RD, Barkovich AJ, 
Sherr EH (2015) De novo mutations in KIF1A cause progressive 
encephalopathy and brain atrophy. Ann Clin Transl Neurol 
2(6):623–635. doi:10.1002/acn3.198 
9. Lee JR, Srour M, Kim D, Hamdan FF, Lim SH, Brunel-Guitton 
C, Decarie JC, Rossignol E, Mitchell GA, Schreiber A, Moran R, 
Van Haren K, Richardson R, Nicolai J, Oberndorff KM, Wagner 
JD, Boycott KM, Rahikkala E, Junna N, Tyynismaa H, Cuppen I, 
Verbeek NE, Stumpel CT, Willemsen MA, de Munnik SA, 
Rouleau GA, Kim E, Kamsteeg EJ, Kleefstra T, Michaud JL 
(2015) De novo mutations in the motor domain of KIF1A cause 
cognitive impairment, spastic paraparesis, axonal neuropathy, 
and cerebellar atrophy. Hum Mutat 36:69–78. doi:10.1002/humu. 
22709 
10. Ylikallio E, Kim D, Isohanni P, Auranen M, Kim E, Lonnqvist T, 
Tyynismaa H (2015) Dominant transmission of de novo KIF1A 
motor domain variant underlying pure spastic paraplegia. Eur J 
Hum Genet. doi:10.1038/ejhg.2014.297 
11. Shin H, Wyszynski M, Huh KH, Valtschanoff JG, Lee JR, Ko J, 
Streuli M, Weinberg RJ, Sheng M, Kim E (2003) Association of 
the kinesin motor KIF1A with the multimodular protein liprin-
alpha.     J     Biol     Chem     278:11393–11401.     doi:10.1074/jbc. 
M211874200 
12. Harding AE (1983) Classiﬁcation of the hereditary ataxias and 
paraplegias. Lancet 1(8334):1151–1155. doi:10.1016/S0140-
6736(83)92879-9 
13. Citterio A, Arnoldi A, Panzeri E, D’Angelo MG, Filosto M, 
Dilena R, Arrigoni F, Castelli M, Maghini C, Germiniasi C, 
Menni F, Martinuzzi A, Bresolin N, Bassi MT (2014) Mutations 
in CYP2U1, DDHD2 and GBA2 genes are rare causes of com-
plicated forms of hereditary spastic paraparesis. J Neurol 
267:373–381. doi:10.1007/s00415-013-7206-6 
14. Goizet C, Boukhris A, Mundwiller E, Tallaksen C, Forlani S, 
Toutain A, Carriere N, Paquis V, Depienne C, Durr A, Stevanin 
G, Brice A (2009) Complicated forms of autosomal dominant 
hereditary spastic paraplegia are frequent in SPG10. Hum Mutat 
30:E376–E385. doi:10.1002/humu.20920 
Web Resources 
15. Genome database: http://browser.1000genomes.org/index.html 
16. EVS: http://evs.gs.washington.edu/EVS/ 
17. NCBI dbSNP: http://www.ncbi.nlm.nih.gov/SNP/ 
18. SIFT and Provean: http://sift.jcvi.org/ 
19. MutPred: http://mutpred.mutdb.org/ 
20. Panther: http://www.pantherdb.org/tools/csnpScoreForm.jsp? 
